首页 > 按月查看>2009年第7月 >574-575
PDF 导出
CETP as a Target in HDL-raising Therapy:lessons from APOE*3-Leiden. CETP Transgenic Mice
DOI:
作者:
作者单位:

作者简介:

通讯作者:

基金项目:


CETP as a Target in HDL-raising Therapy:lessons from APOE*3-Leiden. CETP Transgenic Mice
Author:
Affiliation:

Fund Project:

  • 摘要
    • |
  • 图/表
    • |
  • 访问统计
    • |
  • 参考文献
    • |
  • 相似文献
    • |
  • 引证文献
    • |
  • 资源附件
    摘要:

    Background Cardiovascular disease (CVD) is mainly caused by atherosclerosis,for which dyslipidemia (i.e. high (V)LDL-cholesterol (C),high triglycerides and low HDLC is a major risk factor. To reduce the risk to develop CVD,patients with dyslipidemia are usually treated with lipid-lowering drugs including statins and fibrates.

    Abstract:

    Background Cardiovascular disease (CVD) is mainly caused by atherosclerosis,for which dyslipidemia (i.e. high (V)LDL-cholesterol (C),high triglycerides and low HDLC is a major risk factor. To reduce the risk to develop CVD,patients with dyslipidemia are usually treated with lipid-lowering drugs including statins and fibrates.

    参考文献
    相似文献
    引证文献
引用本文

WillekedeHaan, JitskedeVries-vanderWeij, CarolineC. vanderHoogt, JoséW. A. vanderHoorn, JohannesA. Romijn, J. WouterJukema, LouisM. Havekes, HansM. G. Princen, PatrickC. N. Rensen. CETP as a Target in HDL-raising Therapy:lessons from APOE*3-Leiden. CETP Transgenic Mice[J].中国动脉硬化杂志,2009,17(7):574~575.

复制
分享
文章指标
  • 点击次数:
  • 下载次数:
历史
  • 收稿日期:
  • 最后修改日期:
  • 录用日期:
  • 在线发布日期:

您是本站第 访问者

邮编：421001 传真：0734-8160523

电话：0734-8160765 E-mail：dmzzbjb@163.net

中国动脉硬化杂志 ® 2024 网站版权所有